New strategies to increase the uptake of these proven breast cancer risk-reduction interventions in general clinical practice are needed.
Rowan T. Chlebowski, MD, PhD
Advertisement
Articles by Rowan T. Chlebowski, MD, PhD
Rowan T. Chlebowski, MD, PhD, professor and chief, Harbor-University of California, Los Angeles Medical Center, Department of Internal Medicine, Medical Oncology/Hematology, discusses a planned follow-up analysis of the Women's Health Initiative Dietary Modification study, which examined the impact of reduced dietary fat intake in patients with breast cancer.
Advertisement
Latest Updated Articles
Dr. Chlebowski on Dietary Modifications in Patients With Breast CancerPublished: July 17th 2015 | Updated:
Breast Cancer Chemoprevention: Targeting the Estrogen ReceptorPublished: January 31st 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
4
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
5